Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Investor Presentation (June 2026)
28 slides from Vivani Medical's investor presentation, Jun 4, 2026
Slide 1: Vivani Medical, Inc. - Guaranteed Adherence. Better Outcomes.
20Ce, Vivanir Nasdaq: VANI Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. June 4, 2026
Slide 2: Disclaimers
Disclaimers The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the “safe ha
Slide 3: The obesity market is evolving
The obesity market is evolving What will it take to be successful in the future? In addition to the currently FDA-approved products on the market, there are over 50 in clinical development. All of these are injectables or orals. Vivani’s implant uniquely combines infrequent (e.g., once- or twice-yea
Slide 4: Differentiated product candidates designed to address unmet needs and expand the market
Vivani's differentiated product candidates are designed to address unmet needs and expand the market gw 00, Vivani Market Challenges Suboptimal outcomes Poor medication adherence (<50%) leads to loss of efficacy and rapid weight rebound Tolerability issues Dose fluctuations and pharmacokinetic (PK)
Slide 5: Vivani Medical, Inc.
Vivani Medical, Inc. A clinical stage innovator uniquely positioned to address the future challenges and opportunities of an evolving obesity market Nasdag: VANI diseases via unique route of administration, improved patient adherence, Cash runway expected to tolerability, and convenience fund curren
Slide 6: Company pipeline utilizing NanoPortal platform
Company pipeline utilizing NanoPortal platform If approved, Vivani products would provide a differentiated ultra long-acting option for patients a Obesity/Weight Management Obesity/Weight ixt-generation Management icretins* NPM-139 semaglutide 2 5 Obesity/Weight Management Type2 NPM-133 | Diabetes s
Slide 7: Good things come in small packages
Good things come in small packages GLP-1 implant & applicator Y Simple administration, in-office procedure to insert the implant comfortably under the skin for twice- yearly dosing designed to produce Wegovy®-level efficacy NanoPortal device elements v Designed to assure adherence v Long-term delive
Slide 8: NanoPortal delivers smooth, near-constant drug release
NanoPortal delivers 80 smooth, near-constant S drug release 35 3 2 Gy] aa 40 s 2 2 § 20 = Day 1 timepoint includes cumulative release over the first day including a separately measured 1st hour of release, which was ~7 0 0 30 60 20 720 ug for the high-dose and ~4 pg for the low- dose. Values are mea
Slide 9: In vitro and in vivo performance of 12-week GLP-1 implant configuration
In vitro and in vivo performance of 12-week GLP-1 implant configuration r , T v —#— Sham Implant (Control), n=7 80 | —®~ Exenatide implant. n=? 4 | a ) z £60} 4 2 g |. Ss e f a‘ sa 3 oh y ‘ 4 I : g i a ° . ° ~. @ ° 2 3 20{/ m| 2 F | & | a | —@- Mean, n=17 0 |} _ 4-4-0 a — ap ef ~ = = Upper + Lower 9
Slide 10: Preclinical GLP-1 NanoPortal implant is associated with durable body weight effects
Preclinical GLP-1 NanoPortal implant is associated with durable body weight effects >] | Implant removed 5.0 OUR & & & & ee ee ee ee ee ke 0.0 ; = = -50 | = sol | = z g 10.0 é 10.0 4 15.0 g 8 al SS ba @ -200 7 = -ts0} l 4 F4 * af 3 ’ J Bo ett] , = -200} Te 4 = -v00 a e~. ~25.07 Vehicle Implant (Cont
Slide 11: GLP-1 NanoPortal implant reduced liver fat by 82% in preclinical study
GLP-1 NanoPortal implant reduced liver fat by 82% in preclinical study Liver fat reduction in high fat diet-induced obese mice. Liver fat % area for exenatide implant vs sham implant 12 weeks after a single administration. Values are mean + SE. 008, Vivani Liver fat (% Area) 35.0 30.0 25.0 20.0 15.0
Slide 12: First-in-human GLP-1 NanoPortal clinical trial: LIBERATE-1
First-in-human GLP-1 NanoPortal clinical trial: LIBERATE-1 Primary Objectives Key Inclusion/Exclusion Criteria Safety/tolerability assessment and full pharmacokinetic 18-55 years old; overweight or obese (BMI 27-40) characterization. Changes in weight also assessed. Otherwise healthy (no T2D, normal
Slide 13: LIBERATE-1 topline results summary
LIBERATE-1 topline results summary Implant well-tolerated No serious adverse events in the study No clinically meaningful initial burst Encouraging release profile No evidence of dose dumping Potential for durable long-term delivery confirmed Primary study objectives were met: Further NanoPortal cli
Slide 14: Vivani Lead Program: NPM-139
Vivani Lead Program: NPM-139 SLIM™: Semaglutide ultra Long-acting /Mplant in obesity ee, Vivani
Slide 15: Priority clinical development program: NPM-139
Priority clinical development program: NPM-139 Development of once- or twice-yearly semaglutide implant for chronic weight management in obese or overweight patients oO FDA-approved GLP-1 Based on real-world products generated adherence and $132B in global sales in persistence data, >50% 2025. The m
Slide 16: Persistence and adherence are critical to securing desired long-term health outcomes
Persistence and adherence are critical to securing desired long-term health outcomes Persistence data comparing obesity therapies suggest room for improvement across the board, including for semaglutide. The unmet need is significant. @ The opportunity for an additional 60% improvement in persistenc
Slide 17: Semaglutide discontinuation leads to rapid hunger-induced weight rebound
Semaglutide discontinuation leads to rapid hunger- induced weight rebound Sudden GLP-1 withdrawal produces immediate rebound hunger, leading to rapid weight regain mediated by greater food consumption Body weight (%) — change from baseline 68-week treatment phase . _ S2-week off-treatment ; : extens
Slide 18: NPM-139 provides steady preclinical pharmacokinetics
NPM-139 provides steady preclinical pharmacokinetics In vivo pharmacokinetics of NPM-139 configurations in Sprague-Dawley rats. Values are mean + SE. *n=5 through day 28; two implants removed at Day 28 for characterization, n=3 thereafter. 000, Vivani Plasma Concentration (ng/mL, normalized to 250g)
Slide 19: Prototype semaglutide NanoPortal implant demonstrates sustained weight loss for a full year
Vivani Prototype semaglutide NanoPortal implant demonstrates sustained weight loss and delivery for a full year Prototype NPM-139, prior to PK optimization. /n Vivo Pharmacokinetics and Weight loss vs. control in Sprague- Dawley Rats (A). % weight loss from baseline normalized to a sham-implant cont
Slide 20: Patient and prescriber research indicates strong adoption potential for a 6-month GLP-1 implant
Patient and prescriber research indicates strong adoption potential for a miniature, 6-month GLP-1 implant Currently on a GLP-1 therapy (n=324) cp 33% 42% 14% Ex-GLP-1 therapy (n=178) son =D = GLP-1 therapy naive (n=319) @ Definitely not Unlikely @ Likely @ Definitely Q&A Insights reported market re
Slide 21: NPM-139 clinical and regulatory development: near-term plan builds on recent wins
NPM-139 clinical and regulatory development: Near-term plan builds on recent wins Milestone Status Announced LIBERATE-1 completed and met the primary study objectives August 2025 Reported positive weight loss in preclinical study with semaglutide implant August 2025 Disclosed proposed clinical progr
Slide 22: Proposed NPM-139 Phase 1 study design: SLIM-1
Proposed NPM-139 Phase 1 study design: SLIM-1™ Primary Objectives Key Inclusion/Exclusion Criteria Safety/tolerability assessment and pharmacokinetic 18-55 years old; overweight or obese (BMI 27-40) characterization Otherwise healthy (no T2D) Screen and Treatment (4 Weeks) eoT Randomize (~21 days) V
Slide 23: Proposed NPM-139 Phase 2 study design: SLIM-2
I Proposed NPM-139 Phase 2 study design: SLIM-2™ Randomize Vv Run-In (20 weeks) v Randomized Treatment Period (16 or 24 weeks) 17mg , = is ou. Placebo (sham implant) *unblinded 3
Slide 24: NanoPortal retatrutide implant provides steady preclinical pharmacokinetics
NanoPortal retatrutide implant provides steady preclinical pharmacokinetics in ongoing study In vivo pharmacokinetics of prototype NanoPortal retatrutide implant in Sprague-Dawley rats in an ongoing study. Values are mean + SE. nN 8 © Prototype Nanoportal Retatrutide Implant, n=12 (through day 28),
Slide 25: The Vivani executive leadership team
The Vivani executive leadership team (Y Adam Mendelsohn PhD CEO/Director Co-founder/Co-inventor of Vivani technology PhD Bioengineering (UCSF/UC Berkeley) Management of Technology Certificate at Haas School of Business Research focused on diabetes treatment Formerly at Boston Scientific and MiniMed
Slide 26: Vivani headquarters and GMP manufacturing facility
Vivani headquarters and GMP manufacturing facility
Slide 27: Guaranteed adherence. Improved outcomes.
Guaranteed adherence. Improved outcomes. Only GLP-1 implant in development for obesity and chronic weight management G Convenient once- or twice-yearly dosing expected to address primary GLP-1 market challenges Go @ Unique modality designed to reach underserved & unaddressed populations key to marke
Slide 28: www.vivani.com
www.vivani.com